ProBioGen, lub koom haum kev cog lus tsim thiab tsim khoom lag luam (CDMO), paub txog nws cov kev daws teeb meem tshiab hauv cell engineering thiab bioprocessing zoo tshaj plaws, tshaj tawm kev sib koom tes nrog ModeX Therapeutics ib lub tuam txhab OPKO Health, mob siab rau kev tawm tsam mob qog noj ntshav thiab kab mob sib kis nrog kev txiav ntau yam. tshwj xeeb biologics. ModeX tau kos npe rau Daim Ntawv Pom Zoo Kev Pabcuam Master nrog ProBioGen txhawm rau txhawm rau txhim kho thiab tsim cov khoom siv kho mob ntawm lawv qhov tshwj xeeb COVID-19 tshuaj tiv thaiv. Qhov kev sib tw nqi-rau-kev pabcuam kev sib koom tes no suav nrog tag nrho cov kev pabcuam, suav nrog kev txhim kho cov xovtooj ntawm tes, kev ua kom zoo tshaj plaws, thiab kev tsim GMP loj. ModeX yuav siv lub zog ntawm ProBioGen tus pioneering DirectedLuck® Transposase Technology, uas ua rau cov khoom siv high-titer, ruaj khov qhia cov kab ntawm tes uas tseem ceeb rau txoj kev vam meej ntawm ModeX's antibody program.
Dr. Volker Sandig, CSO ntawm ProBioGen tau hais tias "ProBioGen zoo siab ua haujlwm ntawm ModeX's fascinating complex COVID-19 antibodies. "Peb CHO.RiGHT® platform ua ke nrog DirectedLuck® transposase thev naus laus zis muab lub zog thiab yooj yim los daws cov kev xav tau tshwj xeeb ntawm txhua lub molecule thiab tsim cov kab xov tooj zoo tshaj plaws nrog cov kab nrawm nrawm. tus neeg sib tw tshuaj yeeb. "
Dr. Peter Bernhardt, CMC Lead ntawm ModeX tau hais tias "Peb zoo siab tau koom tes nrog ProBioGen txhawm rau txhim kho peb cov kev pab cuam COVID-19 antibody. "Qhov kev sib koom tes no yog lub sijhawm tseem ceeb hauv peb lub luag haujlwm kom xa cov kev hloov pauv hloov pauv rau cov kab mob sib kis, thiab peb ntseeg siab tias peb cov kws tshaj lij ua ke yuav ua rau muaj txiaj ntsig zoo."
Txoj haujlwm no tau txais nyiaj txiag tag nrho lossis ib feem nrog tsoomfwv cov nyiaj los ntawm Lub Tsev Haujlwm Saib Xyuas Kev Noj Qab Haus Huv thiab Tib Neeg (HHS); Kev tswj hwm rau Kev Npaj Ua Haujlwm Zoo thiab Teb (ASPR); Biomedical Advanced Research thiab Development Authority (BARDA), raws li daim ntawv cog lus 75A50123C00056. Cov nyiaj no yog ib feem ntawm txoj haujlwm NextGen, AN HHS program los ua kom nrawm dua thiab hloov cov tiam kev txhaj tshuaj ntxiv ntawm cov tshuaj tiv thaiv.
Hais txog DirectedLuck®
ProBioGen's DirectedLuck® transposase system ua ke nrog kev ua kom zoo tshaj plaws thiab kev hloov pauv nrog lub hom phiaj epigenetic. Nws yog txawm peem rau nrog ib tug paub qhov chaw rau ib tug tshwj xeeb histone cim uas integrates ntau cov ntawv luam ntawm transgene qhia units ib tus zuj zus nyob rau hauv genomic cheeb tsam nrog siab tshaj transcriptional kev ua ub no. Yog li ntawd, nws ua tiav qhov tshwj xeeb tshaj plaws ntawm cov protein qhia thiab kev ruaj ntseg siab tshaj plaws hauv cov pas dej thiab cov clones. Qhov no txo cov sij hawm thiab phau ntawv chaw ua hauj lwm rau xaiv superior clones rau titers zoo tshaj plaws, pov thawj stability thiab cov khoom zoo.
Lub DirectedLuck® Transposase yog sib xws nrog cov noob caj noob ces hauv cov qauv qhia vector tsim thiab tuaj yeem siv nrog cov tswv tsev ntawm cov kab sib txawv thiab cov ntaub so ntswg. DirectedLuck® muab cov kab xov tooj zoo tshaj plaws rau cov qauv mAbs thiab cov glycoproteins nyuaj thiab muab cov txiaj ntsig ntxiv rau cov kab mob bispecifics thiab cov kab mob tsim cov kab mob uas nws tso cai rau kev hloov pauv ntawm cov txheeb ze qhia qib rau cov khoom zoo.
DirectedLuck® muaj rau kev tso cai tawm. Tsis tas li ntawd, ProBioGen siv DirectedLuck® ua cov cuab yeej txheem hauv cov neeg siv khoom cov haujlwm pabcuam yam tsis tau them nqi ntxiv.